Clinical and pharmacological group: & nbsp

Antibiotics

Included in the formulation
  • Trifamox IBL®
    powder w / m in / in 
    VALEANT, LLC     Russia
  • Trifamox IBL®
    pills inwards 
    VALEANT, LLC     Russia
  • Trifamox IBL®
    powder inwards 
    VALEANT, LLC     Russia
  • Trifamox IBL® DUO
    pills inwards 
    VALEANT, LLC     Russia
  • АТХ:

    J.01.C.R.02   Amoxicillin in combination with enzyme inhibitors

    Pharmacodynamics:

    Amoxicillin

    Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates synthesis biopolymer peptidoglycan - the main component of the bacterial cell wall. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

    A semi-synthetic antibiotic with a broad spectrum of action from the penicillin group is destroyed by the action of β-lactamases.

    Has a bactericidal effect against gram-negative bacteria: Acinetobacter spp., Moraxella catarrhalis, Citrobacter spp. (including Citrobacter freundii, Citrobacter diversus, Citrobacter amalonaticus), Enterobacter spp., Escherichia coli, Haemophilus influenzae, Klebsiella spp. (including Klebsiella pneumoniae), Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas spp. (at including Pseudomonas aeruginosa, Pseudomonas maltophilia), Salmonella spp., Serratia spp. (including Serratia marcescens); gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis (coagulase-negative strains), Staphylococcus saprophyticus, Streptococcus agalactiae (group B), Streptococcus bovis, Enterococcus faecalis, Streptococcus pneumoniae, Streptococcus pyogenes (group A, beta-hemolytic), Streptococcus viridans; anaerobic bacteria: Bacteroides spp., including Bacteroides fragilis group (Bacteroides fragilis, Bacteroides vulgatus, Bacteroides thetaiotaomicronron, Bacteroides ovatus, Bacteroides distasonis) and non-Bacteroides fragilis (beta-melanogenic), Clostridium spp. (including Clostridium perfringens, Clostridium difficile, Clostridium sporogenes, Clostridium ramosum, Clostridium bifermentans), Eubacterium spp., Fusobacterium spp. (including Fusobacterium nucleatum and Fusobacterium necrophorum), Peptococcus spp., Peptostreptococcus spp., Veillonella spp.

    Sulbactam

    It has no clinically significant effect, but, having a β-lactam structure associated with penicillins, competitively inhibits β-lactamase, preventing the inactivation of amoxicillin and expanding its spectrum of activity. It shows bactericidal activity against Neisseriaceae and Acinetobacter.

    Pharmacokinetics:

    Amoxicillin

    After intravenous administration, the maximum concentration in the blood plasma is reached after 30 minutes. After oral administration, up to 80% is absorbed in the gastrointestinal tract. The connection with plasma proteins is 50%.

    Therapeutic effect develops after the reception. Metabolism in the liver.

    The elimination half-life is 1 hour. Elimination by the kidneys.

    Sulbactam

    After intravenous administration, the maximum concentration in the blood plasma is reached after 1 hour. The connection with plasma proteins is 25%. It penetrates the placental barrier and enters the breast milk.

    Metabolism in the liver.

    The elimination half-life is 64 minutes. Elimination by the kidneys.

    The drug is removed during hemodialysis.

    Indications:

    It is used for the treatment of infectious diseases caused by pathogens sensitive to the preparation: bone and connective tissue, skin and subcutaneous tissue, lower respiratory tract, septicemia, peritonitis, endometritis, urinary tract infections and genital tract, including gonorrhea.

    I.A30-A49.A40   Streptococcal septicemia

    I.A30-A49.A41   Other septicemia

    X.J10-J18.J15   Bacterial pneumonia, not elsewhere classified

    X.J20-J22.J20   Acute bronchitis

    X.J40-J47.J42   Chronic bronchitis, unspecified

    XI.K65-K67.K65.0   Acute peritonitis

    XI.K80-K87.K81.0   Acute cholecystitis

    XI.K80-K87.K81.1   Chronic cholecystitis

    XI.K80-K87.K83.0   Cholangitis

    XII.L00-L08.L01   Impetigo

    XII.L00-L08.L02   Abscess of skin, boil and carbuncle

    XII.L00-L08.L03   Phlegmon

    XII.L00-L08.L08.0   Pyoderma

    XIII.M00-M03.M00   Pyogenic arthritis

    XIII.M86-M90.M86   Osteomyelitis

    XIV.N10-N16.N11   Chronic tubulointerstitial nephritis

    XIV.N10-N16.N10   Acute tubulointerstitial nephritis

    XIV.N10-N16.N15.1   Abscess of kidney and adrenal tissue

    XIV.N30-N39.N30   Cystitis

    XIV.N30-N39.N34   Urethritis and urethral syndrome

    XIV.N40-N51.N41   Inflammatory diseases of the prostate

    XIV.N70-N77.N70   Salpingitis and oophoritis

    XIV.N70-N77.N71.0   Acute inflammatory disease of the uterus

    XIV.N70-N77.N71.1   Chronic inflammatory disease of the uterus

    XIV.N70-N77.N72   Inflammatory disease of the cervix

    XIV.N70-N77.N73.0   Acute parametritis and pelvic cellulite

    XIX.T79.T79.3   Post-traumatic wound infection, not elsewhere classified

    XXI.Z20-Z29.Z29.2   Another type of preventive chemotherapy

    Contraindications:

    Individual intolerance to β-lactam antibiotics: penicillins and cephalosporins.

    Carefully:

    Pregnancy, imbalance of electrolytes or fluids, severe liver damage.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used in pregnancy and lactation.

    Dosing and Administration:

    Use in children

    Inside, depending on age:

    up to 2 years - 40-60 mg / kg 2-3 times a day;

    2-6 years - 250 mg 3 times a day;

    6-12 years - 500 mg 3 times a day.

    Adults and teenagers over 12 years of age

    Intravenous or intramuscular 1 g 2-3 times a day.

    The highest daily dose: for amoxicillin - 6 g; for sulbactam - 600 mg.

    Side effects:

    Central and peripheral nervous system: rarely - convulsions.

    Hemopoietic system: thrombocytopenia, eosinophilia, leukopenia, an increase in prothrombin index and coagulation time.

    Digestive system: nausea, vomiting, diarrhea, increased activity of hepatic enzymes, hepatic or cholestatic jaundice, intestinal dysbacteriosis.

    Dermatological reactions: compaction at the injection site, candidiasis dermatitis, vulvovaginitis.

    urinary system: rarely - the development of hypokalemia.

    Allergic reactions.

    Overdose:

    Nausea, vomiting, diarrhea, neuromuscular excitability, convulsive attacks.

    Treatment is symptomatic, hemodialysis.

    Interaction:

    Simultaneous application with probenecid slows the renal excretion of amoxicillin.

    The drug is pharmacologically incompatible with other agents when administered parenterally one solution.

    Special instructions:

    Monitoring of liver and kidney functions with prolonged use.

    Instructions
    Up